June 19, 2023 Dr. Angelo Maria Manzo at BOS Basel 2023: Fostering Collaboration Dr. Angelo Maria Manzo, our esteemed Senior Business Development Manager at Porton Pharma Solutions Ltd.,...
June 19, 2023 Porton Pharma Launches Innovative Small Molecule Platform in Shanghai We are thrilled to announce the establishment of our state-of-the-art Small Molecule Platform in Shanghai,...
June 19, 2023 Dr. Wenfang Miao Joins Porton USA and J-STAR Research as CEO Join us in welcoming Dr. Wenfang Miao (Renee) as the new CEO of Porton Pharma...
June 19, 2023 Serge Kechichian Teams Up for Charity at DCAT Golf Outing Event Our very own Serge Kechichian is all set to tee it up for a cause...
June 19, 2023 Yuriy Abramov, Ph.D. to Share Insights on Pharmaceutical Crystals Join J-STAR Research, Inc. Executive Director of Computational Chemistry and Data Science, Yuriy Abramov, Ph.D.,...
May 14, 2023 Porton Launches Small Molecule Platform at Shanghai Headquarters On May 8, 2023, Porton Pharma Solutions Ltd. (stock code: 300363)...
April 17, 2023 Porton Begins Construction of Antibody and ADC Facility in Shanghai On April 11, 2023, Shanghai Porton Nova Biologics, Ltd., a wholly-owned subsidiary of Porton Pharma...
March 31, 2023 Porton’s Success at DCAT Week 2023: Strategic Insights and Highlights NEW YORK, NY - On March 20th through March 23rd, 2023,...
March 25, 2023 Porton Released 2022 CSR Report Porton Pharma Solutions Ltd. recently released 2022 CSR Report which is its seventh CSR report...